Krystal: Profitable Growth And The Expanding Reach Of HSV-1 Technology

Krystal is leveraging a validated, redosable platform with high margins, profitability, and multiple blockbuster catalysts in CF and NK. Read why KRYS is a Buy.
The Lancet

IL-10-expressing, anti-CD19 CAR T cells for patients with relapsed or refractory B-cell acute lymphoblastic leukaemia: an open-label, single-arm, phase 1 study

aDepartment of Hematology, Centre for Leading Medicine and Advanced Technologies of Institute of Health and Medicine, The First Affiliated Hospital of University of Science and Technology of China, ...
Ophthalmology Times

Results of the APEX phase 1b clinical study of KSI-101 for macular edema

Analysis of the final APEX Phase 1b clinical results obtained with KSI-101 (Kodiak Sciences Inc.) evaluated to treat macular edema secondary to inflammation (MESI) showed that at week 24 well over ...
ascopubs.org

Efficacy and safety of selumetinib in adults with neurofibromatosis type 1 (NF1) and symptomatic, inoperable plexiform neurofibroma (PN): Primary analysis of KOMET (NCT04924608 ...

A first-in-human phase I/II study of GFH375, a highly selective and potent oral KRAS G12D inhibitor in patients with KRAS G12D mutant advanced solid tumors. This is an ASCO Meeting Abstract from the ...